Triple-agonist research peptide · 200 clicks × 0.1mg · Research Use Only
Triple-Agonist Research Peptide

Reta UAE 20mg Pen

GLP-1 + GIP + Glucagon — Three Pathways, One Pen

Buy Reta 20mg Pen in Dubai and the UAE. Pre-filled format with 200 clicks at 0.1mg each, Janoshik COA verification at 99.841% HPLC purity, and pen batch RET-20-C-2604-001 published in our COA library.

20mg per pen Janoshik Verified 99.841% Janoshik HPLC Janoshik Analytical Same-day Dubai delivery
Order Now → Open 20mg Guide
Remy Peptides UAE
Research Only
Reta 20mg Pen with packaging and pen needles
Reta UAE 20mg Pen
Reta UAE 20mg Pen
Triple-agonist research peptide — GLP-1 satiety + GIP insulin + Glucagon expenditure. Pre-filled pen, 200 clicks, cold-chain delivered. Dubai stock with published Janoshik batch verification.
Compound
Reta
CAS 2381089-83-2
Brand / batch
Remy Peptides
RET-20-C-2604-001
Format
Pre-filled pen
200 clicks × 0.1mg
Fulfilment
Same-day Dubai dispatch
Next-day other emirates
Janoshik verification

Janoshik Analytical report for pen batch RET-20-C-2604-001 shows 99.841% HPLC purity at 22.51 mg/mL measured concentration — Task #150762, analyzed 23 Apr 2026. Filed alongside the vial-lot batch-release reports in the COA library. New to reading these reports? See the Peptide COA & HPLC Purity Guide.

Open Purity Report →
In Stock — UAE · 2-4 Hour Delivery Across the UAE
GLP-1 — Satiety
Activates hypothalamic appetite centres to promote satiety signalling. The same receptor targeted by semaglutide, but combined with two additional agonists for triple-pathway activation.
GIP — Insulin
Enhances glucose-dependent insulin secretion and improves beta-cell function. The metabolic layer absent from single-agonist compounds like semaglutide.
Glucagon — Expenditure
Increases hepatic energy expenditure, promotes lipolysis, and enhances thermogenesis. The unique third pathway that differentiates Reta from all other compounds.
Phase 2 — 24.2%
Mean body weight reduction at 48 weeks in the highest-dose cohort. 100% of participants achieved ≥5% weight loss at 24 weeks. Published NEJM 2023.

Janoshik Tested.
Verified Purity.

The current Reta 20mg Pen lot is published with Janoshik Analytical at 99.841% HPLC purity and 22.51 mg/mL measured concentration — Janoshik Task #150762, analyzed 23 Apr 2026 (verification key APSLYZGYW4KA). Review the purity report below, or open the full report.

Janoshik purity report for Reta 20mg batch RET-20-C-2604-001 Janoshik purity report preview — open full report
Laboratory
Janoshik Analytical
Batch
RET-20-C-2604-001
Purity
99.841% HPLC
Concentration
22.51 mg/mL
Analyzed
23 Apr 2026

Reta FAQ

What is Reta?

Reta (LY-3437943) is a novel synthetic triple-agonist peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. It is the first compound to target all three metabolic pathways in a single molecule. In the 48-week Phase 2 trial (n=338), the highest-dose cohort achieved 24.2% mean body weight reduction. CAS: 2381089-83-2.

How does triple agonism differ from semaglutide?

Semaglutide is a single-agonist (GLP-1 only). Tirzepatide is a dual-agonist (GLP-1 + GIP). Reta is the first triple-agonist — activating GLP-1 for satiety signalling, GIP for insulin secretion, and glucagon for hepatic energy expenditure and thermogenesis. This three-pathway approach addresses both energy intake and expenditure simultaneously.

What is the purity?

The current Reta 20mg Pen batch RET-20-C-2604-001 is published with Janoshik Analytical at 99.841% HPLC purity and 22.51 mg/mL measured concentration (Task #150762, analyzed 23 Apr 2026, verification key APSLYZGYW4KA). See the full report in the COA library entry.

What are the pricing tiers?

AED 1,200 per pen (single), AED 3,300 for a 3-pack (AED 1,100/pen), and AED 5,000 for a 5-pack (AED 1,000/pen). Free 2-4 hour UAE delivery on all orders.

How should the pen be stored?

Store at +2 to +8°C (refrigerated). Do not freeze. The Pen is pre-filled — no reconstitution needed. Each pen contains 20mg of Reta delivered across 200 precision clicks at 0.1mg per click. Cold-chain delivered to maintain integrity.

What Phase 2 data exists?

The pivotal Phase 2 trial was published in the New England Journal of Medicine (2023). 338 adults with obesity were randomised across multiple dose cohorts over 48 weeks. The highest-dose group achieved 24.2% mean body weight reduction. 100% of participants in that cohort achieved ≥5% weight loss by week 24. Secondary endpoints showed significant reductions in liver fat content and improvements in cardiometabolic markers.

Is Reta available in the UAE?

Reta is available in Dubai and across the UAE under UAE MoHAP Circular 17/2022 governing research-use compounds. It is not approved for human consumption, therapeutic use, or veterinary use. See our UAE research peptide compliance guide for full detail, or the Reta UAE page for all formats and pricing.

Order Reta — Dubai & UAE

20mg Pen • 200 clicks × 0.1mg • From AED 1,000/pen • Same-day Dubai delivery • WhatsApp confirmation in minutes.

Order Now →
Reta formats

More Reta research formats

Same triple-agonist research compound across pen and vial formats. The 30mg flagship is Janoshik-COA-verified at 99.262% HPLC.

Browse research stacks → — paired Reta + BPC-157 and fat-loss stacks available at 5% off.

Order Now WhatsApp